Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Accounts Payables: 2019-2024

Historic Accounts Payables for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $6.0 million.

  • Kymera Therapeutics' Accounts Payables fell 15.21% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 15.21%. This contributed to the annual value of $6.0 million for FY2024, which is 15.35% down from last year.
  • Kymera Therapeutics' Accounts Payables amounted to $6.0 million in FY2024, which was down 15.35% from $7.1 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Accounts Payables high stood at $7.1 million for FY2023, and its period low was $4.0 million during FY2021.
  • Moreover, its 3-year median value for Accounts Payables was $6.0 million (2024), whereas its average is $5.8 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Accounts Payables skyrocketed by 63.21% in 2023, and later declined by 15.35% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Accounts Payables (Yearly) stood at $4.4 million in 2020, then decreased by 8.31% to $4.0 million in 2021, then climbed by 8.24% to $4.3 million in 2022, then skyrocketed by 63.21% to $7.1 million in 2023, then declined by 15.35% to $6.0 million in 2024.